A new web-based method for automated analysis of muscle histology

BMC Musculoskeletal Disorders

Christian Thirion⁵  Sabine Krause⁴  Maggie C Walter⁴  Hanns Lochmüller³  Erich Wintermantel¹  Stefan Pfeifer¹  Anja Pertl⁴  Markus Eblenkamp²  Cordula Pertl⁴ 

[1] Institute of Medical and Polymer Engineering, Technische Universität München, Munich, Germany;S.CO LifeScience GmbH, Munich, Germany;Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom;Laboratory of Molecular Myology, Friedrich-Baur-Institute, Department of Neurology, Ludwig-Maximilians-Universität München, Marchioninistraße 17, 81377, Munich, Germany;SIRION BIOTECH GmbH, Planegg/Martinsried, Germany

关键词: Minimal Feret’s diameter;    Standardised and automated quantitative analysis;    Histological muscle fibre analysis;    mdx mouse;    Duchenne muscular dystrophy;   

Others  :  1134204
DOI  :  10.1186/1471-2474-14-26

 received in 2012-06-18, accepted in 2013-01-13,  发布年份 2013

【 摘 要 】

Background

Duchenne Muscular Dystrophy is an inherited degenerative neuromuscular disease characterised by rapidly progressive muscle weakness. Currently, curative treatment is not available. Approaches for new treatments that improve muscle strength and quality of life depend on preclinical testing in animal models. The mdx mouse model is the most frequently used animal model for preclinical studies in muscular dystrophy research. Standardised pathology-relevant parameters of dystrophic muscle in mdx mice for histological analysis have been developed in international, collaborative efforts, but automation has not been accessible to most research groups. A standardised and mainly automated quantitative assessment of histopathological parameters in the mdx mouse model is desirable to allow an objective comparison between laboratories.

Methods

Immunological and histochemical reactions were used to obtain a double staining for fast and slow myosin. Additionally, fluorescence staining of the myofibre membranes allows defining the minimal Feret’s diameter. The staining of myonuclei with the fluorescence dye bisbenzimide H was utilised to identify nuclei located internally within myofibres. Relevant structures were extracted from the image as single objects and assigned to different object classes using web-based image analysis (MyoScan). Quantitative and morphometric data were analysed, e.g. the number of nuclei per fibre and minimal Feret’s diameter in 6 month old wild-type C57BL/10 mice and mdx mice.

Results

In the current version of the module “MyoScan”, essential parameters for histologic analysis of muscle sections were implemented including the minimal Feret’s diameter of the myofibres and the automated calculation of the percentage of internally nucleated myofibres. Morphometric data obtained in the present study were in good agreement with previously reported data in the literature and with data obtained from manual analysis.

Conclusions

A standardised and mainly automated quantitative assessment of histopathological parameters in the mdx mouse model is now available. Automated analysis of histological parameters is more rapid and less time-consuming. Moreover, results are unbiased and more reliable. Efficacy of therapeutic interventions, e.g. within the scope of a drug screening or therapeutic exon skipping, can be monitored. The automatic analysis system MyoScan used in this study is not limited exclusively to dystrophin-deficient mice but also represents a useful tool for applications in the research of other dystrophic pathologies, various other skeletal muscle diseases and degenerative neuromuscular disorders.

【 授权许可】

   
2013 Pertl et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Kunkel LM, Monaco AP, Bertelson CJ, Colletti CA: Molecular genetics of Duchenne muscular dystrophy. Cold Spring Harb Symp Quant Biol 1986, 51:349-351.
• [2]Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM: Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987, 50:509-517.
• [3]Rando TA: The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. Muscle Nerve 2001, 24:1575-1594.
• [4]Rentschler S, Linn H, Deininger K, Bedford MT, Espanel X, Sudol M: The WW domain of dystrophin requires EF-hands region to interact with beta dystroglycan. Biol Chem 1999, 380:431-442.
• [5]Campbell KP, Kahl SD: Association of dystrophin and an integral membrane glycoprotein. Nature 1989, 338:259-262.
• [6]Wells DJ: Treatments for muscular dystrophy, increased treatment options for Duchenne and related muscular dystropies. Gene Ther 2008, 15:1077-1078.
• [7]Manzur AY, Kuntzer T, Pike M, Swan A: Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008, 1:CD003725.
• [8]Bulfield G, Siller WG, Wight PA, Moore KJ: X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci USA 1984, 81(4):1189-1192.
• [9]Karpati G, Carpenter S, Prescott S: Small-caliber skeletal muscle fibers do not suffer necrosis in mdx mouse dystrophy. Muscle Nerve 1988, 11:795-803.
• [10]Turk R, Sterrenburg E, de Meijer E, van Ommen G, den Dunnen J, t Hoen P: Muscle regenerationin dystrophin-deficient mdx mice studied by gene expression profiling. BMC Genomics 2005, 6:98. BioMed Central Full Text
• [11]Louboutin P, Fichter-Gagnepain V, Thaon E, Fardeau M: Morphometric analysis of mdx diaphragm muscle fibres. Comparison with hindlimb muscles. Neuromuscul Disord 1993, 3:463-469.
• [12]Briguet A, Courdier-Fruh I, Foster M, Meier T, Magyar JP: Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse. Neuromuscul Disord 2004, 14:675-682.
• [13]Grounds MD, Radley HG, Lynch GS, Nagaraju K, De Luca A: Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol Dis 2008, 31:1-19.
• [14]Schneider CA, Rasband WS, Eliceiri KW: NIH Image to ImageJ: 25 years of image analysis. Nature Methods 2012, 9:671-675.
• [15]Bland JM, Altman DG: Statistical method for assessing agreement between two methods of clinical measurement. Lancet 1986, i:307-310.
• [16]Bland JM, Altman DG: Comparing methods of measurement: why plotting difference against standard method is misleading. Lancet 1995, 346:1085-1087.
• [17]Hanneman SK: Design, analysis, and interpretation of method-comparison studies. AACN Adv Critic Care 2008, 19:223-234.
• [18]Giacomotto J, Pertl C, Borrel C, et al.: Evaluation of the therapeutic potential of carbonic anhydrase inhibitors in two animal models of dystrophin deficient muscular dystrophy. Hum Mol Genet 2009, 18(21):4089-4101.
• [19]Willmann R, Possekel S, Dubach-Powell J, Meier T, Ruegg MA: Mammalian animal models for Duchenne muscular dystrophy. Neuromuscul Disord 2009, 19:241-249.
• [20]Spurney CF, Gordish-Dressman H, Guerron AD, et al.: Preclinical drug trials in the mdx mouse, assessment of reliable and sensitive outcome measures. Muscle Nerve 2009, 39:591-602.